ALIMLIEVA 100MG ( Pemetrexed Injection IP 100mg )

ALIMLIEVA 100 mg contains Pemetrexed, a chemotherapy (anticancer) medicine classified as a multitargeted antifolate. It inhibits several enzymes involved in DNA and RNA synthesis, leading to suppression of cancer cell growth. It is mainly used in non-squamous lung cancers.

Pemetrexed Injection is indicated for:

1. Non-small cell lung cancer (NSCLC) – non-squamous type

   •   First-line therapy (with cisplatin)
   •   Maintenance therapy after initial chemotherapy

2. Malignant pleural mesothelioma

   •   In combination with cisplatin

Common side effects:

•   Fatigue

•   Nausea and vomiting

•   Loss of appetite

•   Anemia, neutropenia, thrombocytopenia

•   Skin rash

•   Mouth sores (stomatitis)

Serious side effects:

•   Severe bone marrow suppression

•   Infections due to low white blood cells

•   Kidney function impairment

•   Severe skin reactions

Vitamin supplementation (Folic acid & Vitamin B12) is mandatory to reduce toxicity.

Dose is calculated based on body surface area (BSA).

Standard dose:

•   500 mg/m² IV infusion on Day 1 of each 21-day cycle

 Administered as intravenous infusion under oncologist supervision.

Supplementation protocol:

•   Folic acid: 350–1000 mcg orally daily (start 7 days before therapy)

•   Vitamin B12: 1000 mcg IM every 9 weeks

•   Dexamethasone: to reduce skin reactions


NOTE: This medicine should be taken only under a doctor’s supervision.